JP2022130646A - 脳送達タンパク質 - Google Patents
脳送達タンパク質 Download PDFInfo
- Publication number
- JP2022130646A JP2022130646A JP2022106495A JP2022106495A JP2022130646A JP 2022130646 A JP2022130646 A JP 2022130646A JP 2022106495 A JP2022106495 A JP 2022106495A JP 2022106495 A JP2022106495 A JP 2022106495A JP 2022130646 A JP2022130646 A JP 2022130646A
- Authority
- JP
- Japan
- Prior art keywords
- protein
- brain
- antibody
- target
- scfv8d3
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 102000004169 proteins and genes Human genes 0.000 title claims abstract description 162
- 108090000623 proteins and genes Proteins 0.000 title claims abstract description 162
- 210000004556 brain Anatomy 0.000 title claims abstract description 137
- 230000027455 binding Effects 0.000 claims abstract description 113
- 230000008499 blood brain barrier function Effects 0.000 claims abstract description 56
- 210000001218 blood-brain barrier Anatomy 0.000 claims abstract description 56
- 210000002889 endothelial cell Anatomy 0.000 claims abstract description 27
- 210000004899 c-terminal region Anatomy 0.000 claims abstract description 21
- 238000003745 diagnosis Methods 0.000 claims abstract description 19
- 208000014644 Brain disease Diseases 0.000 claims abstract description 16
- 208000015122 neurodegenerative disease Diseases 0.000 claims abstract description 14
- 230000003993 interaction Effects 0.000 claims abstract description 9
- 210000005171 mammalian brain Anatomy 0.000 claims abstract description 4
- 108010033576 Transferrin Receptors Proteins 0.000 claims description 47
- 102000003802 alpha-Synuclein Human genes 0.000 claims description 29
- 108090000185 alpha-Synuclein Proteins 0.000 claims description 29
- 108090000765 processed proteins & peptides Proteins 0.000 claims description 29
- 208000024827 Alzheimer disease Diseases 0.000 claims description 21
- 238000000034 method Methods 0.000 claims description 21
- 125000000539 amino acid group Chemical group 0.000 claims description 19
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 18
- 238000001727 in vivo Methods 0.000 claims description 17
- 201000002832 Lewy body dementia Diseases 0.000 claims description 16
- 201000010374 Down Syndrome Diseases 0.000 claims description 14
- 208000009829 Lewy Body Disease Diseases 0.000 claims description 14
- 208000030886 Traumatic Brain injury Diseases 0.000 claims description 14
- 206010002026 amyotrophic lateral sclerosis Diseases 0.000 claims description 14
- 239000012634 fragment Substances 0.000 claims description 14
- 230000009529 traumatic brain injury Effects 0.000 claims description 14
- 238000011282 treatment Methods 0.000 claims description 14
- 241000124008 Mammalia Species 0.000 claims description 13
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 13
- 208000035475 disorder Diseases 0.000 claims description 13
- 108020001507 fusion proteins Proteins 0.000 claims description 13
- 102000037865 fusion proteins Human genes 0.000 claims description 13
- 208000018737 Parkinson disease Diseases 0.000 claims description 12
- 230000001225 therapeutic effect Effects 0.000 claims description 11
- 239000000178 monomer Substances 0.000 claims description 10
- 238000001514 detection method Methods 0.000 claims description 9
- 201000001320 Atherosclerosis Diseases 0.000 claims description 8
- 206010012289 Dementia Diseases 0.000 claims description 8
- 102100033400 4F2 cell-surface antigen heavy chain Human genes 0.000 claims description 7
- 101000800023 Homo sapiens 4F2 cell-surface antigen heavy chain Proteins 0.000 claims description 7
- 101000605020 Homo sapiens Large neutral amino acids transporter small subunit 1 Proteins 0.000 claims description 7
- 102000003746 Insulin Receptor Human genes 0.000 claims description 7
- 108010001127 Insulin Receptor Proteins 0.000 claims description 7
- 208000001089 Multiple system atrophy Diseases 0.000 claims description 7
- 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
- 208000034799 Tauopathies Diseases 0.000 claims description 7
- 210000004558 lewy body Anatomy 0.000 claims description 7
- 208000022256 primary systemic amyloidosis Diseases 0.000 claims description 7
- 230000004845 protein aggregation Effects 0.000 claims description 7
- 208000020406 Creutzfeldt Jacob disease Diseases 0.000 claims description 6
- 208000003407 Creutzfeldt-Jakob Syndrome Diseases 0.000 claims description 6
- 208000010859 Creutzfeldt-Jakob disease Diseases 0.000 claims description 6
- 201000011240 Frontotemporal dementia Diseases 0.000 claims description 6
- 108010021625 Immunoglobulin Fragments Proteins 0.000 claims description 6
- 102000008394 Immunoglobulin Fragments Human genes 0.000 claims description 6
- 208000028017 Psychotic disease Diseases 0.000 claims description 6
- 102000019197 Superoxide Dismutase Human genes 0.000 claims description 6
- 108010012715 Superoxide dismutase Proteins 0.000 claims description 6
- 102000004338 Transferrin Human genes 0.000 claims description 6
- 108090000901 Transferrin Proteins 0.000 claims description 6
- 206010044688 Trisomy 21 Diseases 0.000 claims description 6
- 239000012581 transferrin Substances 0.000 claims description 6
- 101100393884 Drosophila melanogaster Glut1 gene Proteins 0.000 claims description 5
- 208000034846 Familial Amyloid Neuropathies Diseases 0.000 claims description 5
- 101150058068 SLC2A1 gene Proteins 0.000 claims description 5
- 101150084157 lrp-1 gene Proteins 0.000 claims description 5
- 201000000980 schizophrenia Diseases 0.000 claims description 5
- 108010043324 Amyloid Precursor Protein Secretases Proteins 0.000 claims description 4
- 102000002659 Amyloid Precursor Protein Secretases Human genes 0.000 claims description 4
- 101710137189 Amyloid-beta A4 protein Proteins 0.000 claims description 4
- 102100022704 Amyloid-beta precursor protein Human genes 0.000 claims description 4
- 101710151993 Amyloid-beta precursor protein Proteins 0.000 claims description 4
- 208000023105 Huntington disease Diseases 0.000 claims description 4
- -1 P-secretase 1 Proteins 0.000 claims description 4
- 108010071690 Prealbumin Proteins 0.000 claims description 4
- 102100028770 Transmembrane protein 50A Human genes 0.000 claims description 4
- 101710193348 Transmembrane protein 50A Proteins 0.000 claims description 4
- DZHSAHHDTRWUTF-SIQRNXPUSA-N amyloid-beta polypeptide 42 Chemical compound C([C@@H](C(=O)N[C@@H](C)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@H](C(=O)NCC(=O)N[C@@H](CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CCCCN)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)NCC(=O)N[C@@H](C(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](C)C(O)=O)[C@@H](C)CC)C(C)C)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@@H](NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1N=CNC=1)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC=1C=CC=CC=1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@@H](N)CC(O)=O)C(C)C)C(C)C)C1=CC=CC=C1 DZHSAHHDTRWUTF-SIQRNXPUSA-N 0.000 claims description 4
- 108010090849 Amyloid beta-Peptides Proteins 0.000 claims description 3
- 102000013455 Amyloid beta-Peptides Human genes 0.000 claims description 3
- 101000834898 Homo sapiens Alpha-synuclein Proteins 0.000 claims description 3
- 108010060159 Apolipoprotein E4 Proteins 0.000 claims description 2
- 102100022005 B-lymphocyte antigen CD20 Human genes 0.000 claims description 2
- 206010067889 Dementia with Lewy bodies Diseases 0.000 claims description 2
- 102000001301 EGF receptor Human genes 0.000 claims description 2
- 108060006698 EGF receptor Proteins 0.000 claims description 2
- 101800003838 Epidermal growth factor Proteins 0.000 claims description 2
- HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 claims description 2
- 101000897405 Homo sapiens B-lymphocyte antigen CD20 Proteins 0.000 claims description 2
- 101000619542 Homo sapiens E3 ubiquitin-protein ligase parkin Proteins 0.000 claims description 2
- 101000941879 Homo sapiens Leucine-rich repeat serine/threonine-protein kinase 2 Proteins 0.000 claims description 2
- 102100032693 Leucine-rich repeat serine/threonine-protein kinase 2 Human genes 0.000 claims description 2
- 102100040705 Low-density lipoprotein receptor-related protein 8 Human genes 0.000 claims description 2
- 102000007339 Nerve Growth Factor Receptors Human genes 0.000 claims description 2
- 108010032605 Nerve Growth Factor Receptors Proteins 0.000 claims description 2
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
- 108010036908 Presenilin-2 Proteins 0.000 claims description 2
- 102000012419 Presenilin-2 Human genes 0.000 claims description 2
- 108091000054 Prion Proteins 0.000 claims description 2
- 102100033237 Pro-epidermal growth factor Human genes 0.000 claims description 2
- 108091006296 SLC2A1 Proteins 0.000 claims description 2
- 102000004584 Somatomedin Receptors Human genes 0.000 claims description 2
- 108010017622 Somatomedin Receptors Proteins 0.000 claims description 2
- 108010088160 Staphylococcal Protein A Proteins 0.000 claims description 2
- 102100022205 Tumor necrosis factor receptor superfamily member 21 Human genes 0.000 claims description 2
- 101710187751 Tumor necrosis factor receptor superfamily member 21 Proteins 0.000 claims description 2
- 229940116977 epidermal growth factor Drugs 0.000 claims description 2
- 239000003102 growth factor Substances 0.000 claims description 2
- 230000010005 growth-factor like effect Effects 0.000 claims description 2
- 229960002897 heparin Drugs 0.000 claims description 2
- 229920000669 heparin Polymers 0.000 claims description 2
- 108010031117 low density lipoprotein receptor-related protein 8 Proteins 0.000 claims description 2
- 102000045222 parkin Human genes 0.000 claims description 2
- 108010025221 plasma protein Z Proteins 0.000 claims description 2
- 108010026424 tau Proteins Proteins 0.000 claims description 2
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 claims description 2
- 102000007238 Transferrin Receptors Human genes 0.000 claims 3
- 230000002265 prevention Effects 0.000 claims 3
- 208000003808 Amyloid Neuropathies Diseases 0.000 claims 1
- 108090000567 Caspase 7 Proteins 0.000 claims 1
- 102000004041 Caspase 7 Human genes 0.000 claims 1
- 108010001831 LDL receptors Proteins 0.000 claims 1
- 102100024640 Low-density lipoprotein receptor Human genes 0.000 claims 1
- 102000014413 Neuregulin Human genes 0.000 claims 1
- 108050003475 Neuregulin Proteins 0.000 claims 1
- 102000029797 Prion Human genes 0.000 claims 1
- 102100029290 Transthyretin Human genes 0.000 claims 1
- 229910052698 phosphorus Inorganic materials 0.000 claims 1
- 239000011574 phosphorus Substances 0.000 claims 1
- 230000000069 prophylactic effect Effects 0.000 claims 1
- 238000011321 prophylaxis Methods 0.000 claims 1
- 238000011160 research Methods 0.000 abstract description 8
- 238000002560 therapeutic procedure Methods 0.000 abstract description 3
- 235000018102 proteins Nutrition 0.000 description 115
- 241000699670 Mus sp. Species 0.000 description 44
- 102100026144 Transferrin receptor protein 1 Human genes 0.000 description 44
- 238000002347 injection Methods 0.000 description 39
- 239000007924 injection Substances 0.000 description 39
- 239000008280 blood Substances 0.000 description 35
- 241001465754 Metazoa Species 0.000 description 31
- 210000004369 blood Anatomy 0.000 description 29
- 238000002600 positron emission tomography Methods 0.000 description 27
- 238000002965 ELISA Methods 0.000 description 15
- 238000000338 in vitro Methods 0.000 description 15
- 235000001014 amino acid Nutrition 0.000 description 12
- 150000001413 amino acids Chemical class 0.000 description 11
- 210000005013 brain tissue Anatomy 0.000 description 11
- 238000002474 experimental method Methods 0.000 description 11
- 230000032258 transport Effects 0.000 description 11
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 description 10
- 238000009826 distribution Methods 0.000 description 9
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 8
- 210000001638 cerebellum Anatomy 0.000 description 8
- 238000010586 diagram Methods 0.000 description 8
- 230000000694 effects Effects 0.000 description 8
- 238000005304 joining Methods 0.000 description 8
- 108010064397 amyloid beta-protein (1-40) Proteins 0.000 description 7
- 230000037396 body weight Effects 0.000 description 7
- 230000003902 lesion Effects 0.000 description 7
- 210000000056 organ Anatomy 0.000 description 7
- 239000000872 buffer Substances 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 230000003247 decreasing effect Effects 0.000 description 6
- 239000003446 ligand Substances 0.000 description 6
- 102000004196 processed proteins & peptides Human genes 0.000 description 6
- 238000011287 therapeutic dose Methods 0.000 description 6
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 description 5
- 108010001336 Horseradish Peroxidase Proteins 0.000 description 5
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 description 5
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 description 5
- PNDPGZBMCMUPRI-XXSWNUTMSA-N [125I][125I] Chemical compound [125I][125I] PNDPGZBMCMUPRI-XXSWNUTMSA-N 0.000 description 5
- 238000000376 autoradiography Methods 0.000 description 5
- 238000010494 dissociation reaction Methods 0.000 description 5
- 230000005593 dissociations Effects 0.000 description 5
- 239000003814 drug Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 235000019253 formic acid Nutrition 0.000 description 5
- 238000011534 incubation Methods 0.000 description 5
- 102000005962 receptors Human genes 0.000 description 5
- 108020003175 receptors Proteins 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 210000001519 tissue Anatomy 0.000 description 5
- 239000013598 vector Substances 0.000 description 5
- 102000014914 Carrier Proteins Human genes 0.000 description 4
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 4
- 101000798441 Homo sapiens Basigin Proteins 0.000 description 4
- 238000012404 In vitro experiment Methods 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- NIJJYAXOARWZEE-UHFFFAOYSA-N Valproic acid Chemical compound CCCC(C(O)=O)CCC NIJJYAXOARWZEE-UHFFFAOYSA-N 0.000 description 4
- 108091008324 binding proteins Proteins 0.000 description 4
- 230000002490 cerebral effect Effects 0.000 description 4
- 239000012895 dilution Substances 0.000 description 4
- 238000010790 dilution Methods 0.000 description 4
- 229940079593 drug Drugs 0.000 description 4
- 210000001163 endosome Anatomy 0.000 description 4
- 238000003384 imaging method Methods 0.000 description 4
- 238000012744 immunostaining Methods 0.000 description 4
- 229940044173 iodine-125 Drugs 0.000 description 4
- 229910052742 iron Inorganic materials 0.000 description 4
- 238000002372 labelling Methods 0.000 description 4
- 230000000670 limiting effect Effects 0.000 description 4
- 230000014759 maintenance of location Effects 0.000 description 4
- 230000001404 mediated effect Effects 0.000 description 4
- 238000012986 modification Methods 0.000 description 4
- 230000004048 modification Effects 0.000 description 4
- 230000035772 mutation Effects 0.000 description 4
- 230000010412 perfusion Effects 0.000 description 4
- 230000002093 peripheral effect Effects 0.000 description 4
- 125000001500 prolyl group Chemical group [H]N1C([H])(C(=O)[*])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 4
- 239000011780 sodium chloride Substances 0.000 description 4
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 3
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Natural products NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 3
- 102000009190 Transthyretin Human genes 0.000 description 3
- 108010064539 amyloid beta-protein (1-42) Proteins 0.000 description 3
- 238000004458 analytical method Methods 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 235000011089 carbon dioxide Nutrition 0.000 description 3
- 238000006243 chemical reaction Methods 0.000 description 3
- 238000010367 cloning Methods 0.000 description 3
- 230000008030 elimination Effects 0.000 description 3
- 238000003379 elimination reaction Methods 0.000 description 3
- 210000002216 heart Anatomy 0.000 description 3
- 210000001320 hippocampus Anatomy 0.000 description 3
- 239000002609 medium Substances 0.000 description 3
- 239000000203 mixture Substances 0.000 description 3
- 210000001577 neostriatum Anatomy 0.000 description 3
- 210000002569 neuron Anatomy 0.000 description 3
- 239000000902 placebo Substances 0.000 description 3
- 229940068196 placebo Drugs 0.000 description 3
- 238000000746 purification Methods 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 230000000717 retained effect Effects 0.000 description 3
- 241000894007 species Species 0.000 description 3
- 210000000952 spleen Anatomy 0.000 description 3
- 210000001103 thalamus Anatomy 0.000 description 3
- 230000031998 transcytosis Effects 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 2
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 2
- 102100021257 Beta-secretase 1 Human genes 0.000 description 2
- 238000011740 C57BL/6 mouse Methods 0.000 description 2
- 239000004471 Glycine Substances 0.000 description 2
- 241000282412 Homo Species 0.000 description 2
- 101000894895 Homo sapiens Beta-secretase 1 Proteins 0.000 description 2
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- 229920002873 Polyethylenimine Polymers 0.000 description 2
- 108010090804 Streptavidin Proteins 0.000 description 2
- 230000009056 active transport Effects 0.000 description 2
- 230000032683 aging Effects 0.000 description 2
- 230000033228 biological regulation Effects 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 230000036765 blood level Effects 0.000 description 2
- 210000001175 cerebrospinal fluid Anatomy 0.000 description 2
- VDQQXEISLMTGAB-UHFFFAOYSA-N chloramine T Chemical compound [Na+].CC1=CC=C(S(=O)(=O)[N-]Cl)C=C1 VDQQXEISLMTGAB-UHFFFAOYSA-N 0.000 description 2
- 230000002860 competitive effect Effects 0.000 description 2
- 230000001627 detrimental effect Effects 0.000 description 2
- 238000002059 diagnostic imaging Methods 0.000 description 2
- 239000012636 effector Substances 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 235000013305 food Nutrition 0.000 description 2
- 238000009472 formulation Methods 0.000 description 2
- 238000009169 immunotherapy Methods 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 239000011630 iodine Substances 0.000 description 2
- 229910052740 iodine Inorganic materials 0.000 description 2
- 229960002725 isoflurane Drugs 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 102000039446 nucleic acids Human genes 0.000 description 2
- 108020004707 nucleic acids Proteins 0.000 description 2
- 150000007523 nucleic acids Chemical class 0.000 description 2
- JPMIIZHYYWMHDT-UHFFFAOYSA-N octhilinone Chemical compound CCCCCCCCN1SC=CC1=O JPMIIZHYYWMHDT-UHFFFAOYSA-N 0.000 description 2
- 230000007170 pathology Effects 0.000 description 2
- 230000037361 pathway Effects 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 239000000546 pharmaceutical excipient Substances 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 235000013930 proline Nutrition 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 239000000523 sample Substances 0.000 description 2
- HRZFUMHJMZEROT-UHFFFAOYSA-L sodium disulfite Chemical compound [Na+].[Na+].[O-]S(=O)S([O-])(=O)=O HRZFUMHJMZEROT-UHFFFAOYSA-L 0.000 description 2
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 2
- 229940001584 sodium metabisulfite Drugs 0.000 description 2
- 235000010262 sodium metabisulphite Nutrition 0.000 description 2
- 238000007619 statistical method Methods 0.000 description 2
- 239000011550 stock solution Substances 0.000 description 2
- 229960001479 tosylchloramide sodium Drugs 0.000 description 2
- 230000009261 transgenic effect Effects 0.000 description 2
- 238000011830 transgenic mouse model Methods 0.000 description 2
- 229960000604 valproic acid Drugs 0.000 description 2
- 210000003462 vein Anatomy 0.000 description 2
- 238000012800 visualization Methods 0.000 description 2
- MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 1
- 102100034452 Alternative prion protein Human genes 0.000 description 1
- 208000037259 Amyloid Plaque Diseases 0.000 description 1
- 241000283690 Bos taurus Species 0.000 description 1
- 241000282472 Canis lupus familiaris Species 0.000 description 1
- 241000283707 Capra Species 0.000 description 1
- 102000004018 Caspase 6 Human genes 0.000 description 1
- 108090000425 Caspase 6 Proteins 0.000 description 1
- 229940123587 Cell cycle inhibitor Drugs 0.000 description 1
- 241000282693 Cercopithecidae Species 0.000 description 1
- 241000122205 Chamaeleonidae Species 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 241000283086 Equidae Species 0.000 description 1
- 241000282326 Felis catus Species 0.000 description 1
- BDAGIHXWWSANSR-UHFFFAOYSA-M Formate Chemical compound [O-]C=O BDAGIHXWWSANSR-UHFFFAOYSA-M 0.000 description 1
- GYHNNYVSQQEPJS-YPZZEJLDSA-N Gallium-68 Chemical compound [68Ga] GYHNNYVSQQEPJS-YPZZEJLDSA-N 0.000 description 1
- BCCRXDTUTZHDEU-VKHMYHEASA-N Gly-Ser Chemical compound NCC(=O)N[C@@H](CO)C(O)=O BCCRXDTUTZHDEU-VKHMYHEASA-N 0.000 description 1
- 101001024703 Homo sapiens Nck-associated protein 5 Proteins 0.000 description 1
- 102000017727 Immunoglobulin Variable Region Human genes 0.000 description 1
- 108010067060 Immunoglobulin Variable Region Proteins 0.000 description 1
- AYFVYJQAPQTCCC-GBXIJSLDSA-N L-threonine Chemical compound C[C@@H](O)[C@H](N)C(O)=O AYFVYJQAPQTCCC-GBXIJSLDSA-N 0.000 description 1
- 108010015340 Low Density Lipoprotein Receptor-Related Protein-1 Proteins 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 241001529936 Murinae Species 0.000 description 1
- 241000699666 Mus <mouse, genus> Species 0.000 description 1
- 241000699660 Mus musculus Species 0.000 description 1
- 102100036946 Nck-associated protein 5 Human genes 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 241000288906 Primates Species 0.000 description 1
- ONIBWKKTOPOVIA-UHFFFAOYSA-N Proline Natural products OC(=O)C1CCCN1 ONIBWKKTOPOVIA-UHFFFAOYSA-N 0.000 description 1
- 102100021923 Prolow-density lipoprotein receptor-related protein 1 Human genes 0.000 description 1
- 108010076504 Protein Sorting Signals Proteins 0.000 description 1
- 241000700159 Rattus Species 0.000 description 1
- 241000283984 Rodentia Species 0.000 description 1
- MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 1
- AYFVYJQAPQTCCC-UHFFFAOYSA-N Threonine Natural products CC(O)C(N)C(O)=O AYFVYJQAPQTCCC-UHFFFAOYSA-N 0.000 description 1
- 239000004473 Threonine Substances 0.000 description 1
- 101710120037 Toxin CcdB Proteins 0.000 description 1
- 239000007983 Tris buffer Substances 0.000 description 1
- 238000009825 accumulation Methods 0.000 description 1
- VREFGVBLTWBCJP-UHFFFAOYSA-N alprazolam Chemical compound C12=CC(Cl)=CC=C2N2C(C)=NN=C2CN=C1C1=CC=CC=C1 VREFGVBLTWBCJP-UHFFFAOYSA-N 0.000 description 1
- 150000001408 amides Chemical class 0.000 description 1
- 238000000540 analysis of variance Methods 0.000 description 1
- 238000009175 antibody therapy Methods 0.000 description 1
- 108010054176 apotransferrin Proteins 0.000 description 1
- OWMVSZAMULFTJU-UHFFFAOYSA-N bis-tris Chemical compound OCCN(CCO)C(CO)(CO)CO OWMVSZAMULFTJU-UHFFFAOYSA-N 0.000 description 1
- 239000002981 blocking agent Substances 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000005018 casein Substances 0.000 description 1
- BECPQYXYKAMYBN-UHFFFAOYSA-N casein, tech. Chemical compound NCCCCC(C(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(CC(C)C)N=C(O)C(CCC(O)=O)N=C(O)C(CC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(C(C)O)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=N)N=C(O)C(CCC(O)=O)N=C(O)C(CCC(O)=O)N=C(O)C(COP(O)(O)=O)N=C(O)C(CCC(O)=N)N=C(O)C(N)CC1=CC=CC=C1 BECPQYXYKAMYBN-UHFFFAOYSA-N 0.000 description 1
- 235000021240 caseins Nutrition 0.000 description 1
- 230000015556 catabolic process Effects 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 239000003638 chemical reducing agent Substances 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 239000007979 citrate buffer Substances 0.000 description 1
- 238000003776 cleavage reaction Methods 0.000 description 1
- 238000002591 computed tomography Methods 0.000 description 1
- 230000002596 correlated effect Effects 0.000 description 1
- 230000000875 corresponding effect Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000006731 degradation reaction Methods 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 239000000032 diagnostic agent Substances 0.000 description 1
- 229940039227 diagnostic agent Drugs 0.000 description 1
- 239000000539 dimer Substances 0.000 description 1
- 238000006471 dimerization reaction Methods 0.000 description 1
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
- 230000005750 disease progression Effects 0.000 description 1
- 239000003937 drug carrier Substances 0.000 description 1
- 238000005538 encapsulation Methods 0.000 description 1
- 230000003511 endothelial effect Effects 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000007717 exclusion Effects 0.000 description 1
- 239000013604 expression vector Substances 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 125000003630 glycyl group Chemical group [H]N([H])C([H])([H])C(*)=O 0.000 description 1
- 108010033706 glycylserine Proteins 0.000 description 1
- 230000013632 homeostatic process Effects 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 238000002991 immunohistochemical analysis Methods 0.000 description 1
- 238000003364 immunohistochemistry Methods 0.000 description 1
- 238000011065 in-situ storage Methods 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- XMBWDFGMSWQBCA-OIOBTWANSA-N iodane Chemical compound [124IH] XMBWDFGMSWQBCA-OIOBTWANSA-N 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 238000012417 linear regression Methods 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 210000004072 lung Anatomy 0.000 description 1
- 210000003712 lysosome Anatomy 0.000 description 1
- 230000001868 lysosomic effect Effects 0.000 description 1
- 210000004962 mammalian cell Anatomy 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 239000003550 marker Substances 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 230000007246 mechanism Effects 0.000 description 1
- 230000003278 mimic effect Effects 0.000 description 1
- 210000003205 muscle Anatomy 0.000 description 1
- 201000001119 neuropathy Diseases 0.000 description 1
- 230000007823 neuropathy Effects 0.000 description 1
- 210000000440 neutrophil Anatomy 0.000 description 1
- 230000009871 nonspecific binding Effects 0.000 description 1
- 238000001543 one-way ANOVA Methods 0.000 description 1
- 210000000496 pancreas Anatomy 0.000 description 1
- 239000012188 paraffin wax Substances 0.000 description 1
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
- 208000033808 peripheral neuropathy Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- ISWSIDIOOBJBQZ-UHFFFAOYSA-N phenol group Chemical group C1(=CC=CC=C1)O ISWSIDIOOBJBQZ-UHFFFAOYSA-N 0.000 description 1
- 238000010149 post-hoc-test Methods 0.000 description 1
- 239000002243 precursor Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 238000000159 protein binding assay Methods 0.000 description 1
- 239000012474 protein marker Substances 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000002287 radioligand Substances 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 229920006395 saturated elastomer Polymers 0.000 description 1
- 230000007017 scission Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000009870 specific binding Effects 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 239000000126 substance Substances 0.000 description 1
- 239000000758 substrate Substances 0.000 description 1
- 210000000225 synapse Anatomy 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 230000008685 targeting Effects 0.000 description 1
- 238000012360 testing method Methods 0.000 description 1
- 229940124597 therapeutic agent Drugs 0.000 description 1
- 210000001685 thyroid gland Anatomy 0.000 description 1
- 238000003325 tomography Methods 0.000 description 1
- 238000001890 transfection Methods 0.000 description 1
- 239000012096 transfection reagent Substances 0.000 description 1
- LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 1
- GPRLSGONYQIRFK-MNYXATJNSA-N triton Chemical compound [3H+] GPRLSGONYQIRFK-MNYXATJNSA-N 0.000 description 1
- 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 1
- 210000000689 upper leg Anatomy 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/555—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound pre-targeting systems involving an organic compound, other than a peptide, protein or antibody, for targeting specific cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
- A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
- A61P25/16—Anti-Parkinson drugs
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2881—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD71
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
- G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/705—Assays involving receptors, cell surface antigens or cell surface determinants
- G01N2333/70582—CD71
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Immunology (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Molecular Biology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Psychiatry (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Psychology (AREA)
- Epidemiology (AREA)
- Physics & Mathematics (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Food Science & Technology (AREA)
- Biotechnology (AREA)
- Analytical Chemistry (AREA)
- General Physics & Mathematics (AREA)
- Pathology (AREA)
- Peptides Or Proteins (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
Description
本発明は、抗体など、脳内の標的に結合するタンパク質を血液脳関門を越えて輸送することができる脳送達タンパク質に関する。
血液脳関門(BBB)は、緊密に結合した内皮細胞からなり、小さい薬物様分子と大きい分子様タンパク質の両方を脳の外側に保つことにより脳を保護する働きをする。血液脳関門は、脳の恒常性に重要であるが、その存在は脳の病気の治療および診断にとっては障害である。例えば、BBBの緊密に結合した内皮細胞により無修飾抗体の約0.1%のみが脳に侵入する(Bard F. et al, Nat. Med. 6: 916-919 (2000))。
本発明の目的は、脳の病気の治療および診断のため、および研究目的のための新規なタンパク質を提供することである。
哺乳類の脳内の標的に結合する標的結合抗体またはその断片、および
それぞれ、血液脳関門(BBB)内皮細胞表面に発現したタンパク質と一価の相互作用をすることができる2つの担体部位を含み、
前記担体部位のそれぞれは、前記標的結合抗体のC末端側終端に結合している。
RmAb158-scFv8D3のクローニング
%ID/g=組織(または血液)1グラム当たりの測定放射性活性/注入した放射性活性
また、組織対血液(Kp)濃度比を以下のように算出した。
Kp=組織1グラム当たりの測定放射性活性/1グラムの血液の測定放射性活性
Claims (30)
- 哺乳類の脳内の標的に結合する標的結合抗体、および
それぞれが血液脳関門(BBB)内皮細胞表面に発現したタンパク質と一価の相互作用をすることができる2つの担体部位を含み、
前記担体部位のそれぞれは前記標的結合抗体のC末端側終端に結合している、脳送達タンパク質。 - 前記2つの担体部位の一方が前記BBB内皮細胞表面に発現したタンパク質に一度に結合する、請求項1に記載のタンパク質。
- 前記担体部位のそれぞれはリンカーにより前記標的結合抗体に結合している、請求項1または2に記載のタンパク質。
- 前記リンカーのそれぞれは、個別に、1~30個のアミノ酸残基、好ましくは1~25個のアミノ酸残基、好ましくは1~19個のアミノ酸残基、好ましくは3~19個のアミノ酸残基、好ましくは3~15個のアミノ酸残基、好ましくは5~15個のアミノ酸残基からなるアミノ酸配列を持つペプチドを含む、請求項3に記載のタンパク質。
- 前記担体部位のそれぞれは前記標的結合抗体の軽鎖のC末端側終端に結合している、上記請求項の何れか一項に記載のタンパク質。
- 前記担体部位のそれぞれは前記標的結合抗体の重鎖のC末端側終端に結合している、請求項1~4の何れか一項に記載のタンパク質。
- 第一の担体部位は前記標的結合抗体の重鎖のC末端に結合しており、第二の担体部位は前記標的結合抗体の軽鎖のC末端側終端に結合している、請求項1~4の何れか一項に記載のタンパク質。
- 前記担体部位のそれぞれはリンカーにより前記標的結合抗体に結合しており、前記リンカーは配列番号1として表されるアミノ酸配列を持つペプチドを含む、上記請求項の何れか一項に記載のタンパク質。
- 前記担体部位のそれぞれは、scFv、Fv、scFab、またはVHH;トランスフェリンまたはその変異体あるいは多様体、またはブドウ球菌タンパク質AのドメインBに由来するタンパク質Zの多様体より選択される抗体断片を含む、上記請求項の何れか一項に記載のタンパク質。
- 前記担体部位のそれぞれはscFvを含む、請求項9に記載のタンパク質。
- 前記BBB内皮細胞表面に発現したタンパク質は、トランスフェリン受容体(TfR)、インスリン受容体(InsR)、インスリン様成長因子受容体、低密度リポタンパク質受容体関連タンパク質8(Lrp8)、低密度リポタンパク質受容体関連タンパク質1(Lrp1)、CD98、膜貫通タンパク質50A(TMEM50A)、グルコース輸送体1(Glut1)、ベイシジン(BSG)、およびヘパリン結合上皮成長因子様成長因子より選択される、上記請求項の何れか一項に記載のタンパク質。
- 前記BBB内皮細胞表面に発現したタンパク質はTfRである、請求項11に記載のタンパク質。
- 前記前記標的結合抗体は完全な長さの抗体、Fab、F(ab’)2、またはFvである、上記請求項の何れか一項に記載のタンパク質。
- 前記標的結合抗体は完全な長さの抗体である、請求項13に記載のタンパク質。
- 前記脳内の標的は、アミロイドβ(Aβ)ペプチド、αシヌクレイン、スーパーオキシドジスムターゼ(SOD)、ハンチンチン、トランスサイレチン、P-セクレターゼ1、上皮成長因子、上皮成長因子受容体2、タウ、リン酸化タウ、アポリポタンパク質E4、CD20、プリオンタンパク質、ロイシン富化反復キナーゼ2、パーキン、プレセニリン2、γセクレターゼ、細胞死受容体6、アミロイド前駆体タンパク質、p75ニューロトロフィン受容体、ニューレグリン、およびカスパーゼ6より選択される、上記請求項の何れか一項に記載のタンパク質。
- 前記脳の標的は、Aβペプチド、好ましくは可溶性Aβ凝集体、例えば、オリゴマーおよびプロトフィブリルから選択される可溶性Aβ凝集体である、請求項15に記載のタンパク質。
- 前記タンパク質は、Aβ結合抗体、および抗TfR抗体の断片である2つの担体部位を含む、請求項16に記載のタンパク質。
- 前記Aβ結合抗体はmAb158/BAN2401またはその変異体あるいは多様体であり、前記担体部位のそれぞれはscFv8D3であり、前記scFv8D3のそれぞれは、前記mAb158/BAN2401またはその変異体あるいは多様体の軽鎖のC末端側終端に結合しており、前記タンパクは、さらに2つのリンカーを含んでいてもよく、各リンカーは、前記mAb158/BAN2401またはその変異体あるいは多様体に前記scFv8D3を結合するための配列番号1で表されるアミノ酸配列を持つ、請求項17に記載のタンパク質。
- 前記脳の標的は、αシヌクレイン、好ましくは可溶性αシヌクレイン、例えば、オリゴマーおよびプロトフィブリルより選択される可溶性αシヌクレインである、請求項15に記載のタンパク質。
- αシヌクレイン結合抗体、および抗TfR抗体の断片である2つの担体部位を含む、請求項19に記載のタンパク質。
- 前記αシヌクレイン結合抗体はヒトαシヌクレインプロトフィブリルに結合し、前記αシヌクレイン結合抗体はαシヌクレイン単量体に結合しないことが好ましい、請求項20に記載のタンパク質。
- 前記αシヌクレイン結合抗体はmAb48またはその変異体あるいは多様体であり、前記担体部位のそれぞれはscFv8D3であり、前記scFv8D3のそれぞれは、前記mAb48またはその変異体あるいは多様体の軽鎖のC末端側終端に結合しており、前記タンパク質はさらに2つのリンカーを含み、各リンカーは前記scFv8D3を前記mAb48またはその変異体あるいは多様体に結合するための配列番号1で表されるアミノ酸配列を持っていてもよい、請求項20または21に記載のタンパク質。
- 前記タンパク質は融合タンパク質である、上記請求項の何れか一項に記載のタンパク質。
- 予防および/または治療に用いられる、上記請求項の何れか一項に記載のタンパク質。
- 神経変性障害、好ましくはアルツハイマー病、およびAβタンパク質凝集に関連付けられた他の障害、例えば、外傷性脳損傷(TBI)、レビー小体認知症(LBD)、ダウン症候群(DS)、筋萎縮性側索硬化症(ALS)、前頭側頭型認知症、タウオパシー、全身性アミロイド症、アテローム性動脈硬化およびパーキンソン病認知症(PDD);アルツハイマー病のレビー小体多様体;多系統萎縮症;精神病;統合失調症;クロイツフェルト・ヤコブ病;ハンチントン病、および家族性アミロイドニューロパシーからなる群より選択される神経変性障害の治療および/または予防および/または生体内診断に用いられる、請求項24に記載のタンパク質。
- アルツハイマー病の治療および/または予防および/または生体内診断に用いられる、請求項25に記載のタンパク質。
- パーキンソン病の治療および/または予防および/または生体内診断に用いられる、請求項26に記載のタンパク質。
- 脳障害を患っているか、または発症する危険がある哺乳類で前記脳障害を治療および/または予防する方法であって、前記哺乳類に治療有効量の請求項1~23の何れか一項に記載の脳送達タンパク質を投与することを含む、方法。
- 脳障害を患っているか、または発症する危険性があると疑われる哺乳類で前記脳障害を診断および/または検出する方法であって、前記哺乳類に診断および/または検出が可能な十分な量で請求項1~23の何れか一項に記載の脳送達タンパク質を投与することを含む、方法。
- 前記障害は、アルツハイマー病、および外傷性脳損傷(TBI)、レビー小体認知症(LBD)、ダウン症候群(DS)、筋萎縮性側索硬化症(ALS)、前頭側頭型認知症、タウオパシー、全身性アミロイド症、アテローム性動脈硬化およびパーキンソン病認知症(PDD);アルツハイマー病のレビー小体多様体;多系統萎縮症;精神病;統合失調症;クロイツフェルト・ヤコブ病;ハンチントン病、および家族性アミロイドニューロパシーなどのAβタンパク質凝集に関連付けられた他の障害からなる群より選択される神経変性障害などの神経変性障害である、請求項28に記載の治療および/または予防する、または請求項29に記載の診断および/または検出をする方法。
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
SE1651065-3 | 2016-07-14 | ||
SE1651065 | 2016-07-14 | ||
PCT/EP2017/067727 WO2018011353A1 (en) | 2016-07-14 | 2017-07-13 | Brain delivery protein |
JP2019501707A JP2019529345A (ja) | 2016-07-14 | 2017-07-13 | 脳送達タンパク質 |
Related Parent Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501707A Division JP2019529345A (ja) | 2016-07-14 | 2017-07-13 | 脳送達タンパク質 |
Publications (1)
Publication Number | Publication Date |
---|---|
JP2022130646A true JP2022130646A (ja) | 2022-09-06 |
Family
ID=59593007
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501707A Pending JP2019529345A (ja) | 2016-07-14 | 2017-07-13 | 脳送達タンパク質 |
JP2022106495A Pending JP2022130646A (ja) | 2016-07-14 | 2022-06-30 | 脳送達タンパク質 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2019501707A Pending JP2019529345A (ja) | 2016-07-14 | 2017-07-13 | 脳送達タンパク質 |
Country Status (15)
Country | Link |
---|---|
US (1) | US11498974B2 (ja) |
EP (1) | EP3484918A1 (ja) |
JP (2) | JP2019529345A (ja) |
KR (1) | KR20190039696A (ja) |
CN (1) | CN109476728A (ja) |
AU (1) | AU2017297804A1 (ja) |
BR (1) | BR112019000098A2 (ja) |
CA (1) | CA3028035A1 (ja) |
IL (1) | IL263773A (ja) |
MA (1) | MA45684A (ja) |
MX (1) | MX2019000529A (ja) |
PH (1) | PH12018502451A1 (ja) |
RU (1) | RU2019102746A (ja) |
SG (2) | SG11201810801QA (ja) |
WO (1) | WO2018011353A1 (ja) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SI3583120T1 (sl) | 2017-02-17 | 2023-02-28 | Denali Therapeutics Inc. | Inženirani polipeptidi, ki vezujejo transferinske receptorje |
WO2018151821A1 (en) | 2017-02-17 | 2018-08-23 | Bristol-Myers Squibb Company | Antibodies to alpha-synuclein and uses thereof |
CA3118692A1 (en) * | 2018-11-06 | 2020-05-14 | Alsatech, Inc. | Cell-based gene therapy for neurodegenerative diseases |
IL308394A (en) | 2021-06-11 | 2024-01-01 | Bioarctic Ab | The bispecific binding molecule |
WO2023215697A1 (en) * | 2022-05-05 | 2023-11-09 | Eli Lilly And Company | Multispecific binding molecules and methods of use thereof |
WO2024080843A1 (ko) * | 2022-10-14 | 2024-04-18 | 주식회사 아임뉴런 | 뇌혈관장벽 투과성 융합 단백질 및 이의 용도 |
Family Cites Families (15)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2002003911A2 (en) | 2000-07-07 | 2002-01-17 | Lars Lannfelt | Prevention and treatment of alzheimer's disease |
SE0401601D0 (sv) | 2004-06-21 | 2004-06-21 | Bioarctic Neuroscience Ab | Protofibril specific antibodies and uses thereof |
NZ567888A (en) | 2006-03-23 | 2010-08-27 | Bioarctic Neuroscience Ab | Improved protofibril selective antibodies and the use thereof |
US8759297B2 (en) * | 2006-08-18 | 2014-06-24 | Armagen Technologies, Inc. | Genetically encoded multifunctional compositions bidirectionally transported between peripheral blood and the cns |
MX2010011209A (es) | 2008-04-24 | 2010-11-12 | Squibb Bristol Myers Co | Uso de epotilona d en el tratamiento de enfermedades asociadas a tau incluyendo enfermedad de alzheimer. |
WO2009133521A2 (en) | 2008-04-29 | 2009-11-05 | Bioartic Neuroscience Ab | Antibodies and vaccines for use in therapeutic and diagnostic methods for alpha-synuclein-related disorders |
CN104800147A (zh) | 2008-07-10 | 2015-07-29 | 德勒尼克斯治疗股份公司 | 用于大分子的增强的递送的方法和组合物 |
DK2448968T3 (da) | 2009-06-29 | 2021-04-12 | Bioarctic Ab | ANTISTOFFER SOM ER SELEKTIVE FOR N-TERMINAL-TRUNKEREDE AMYLOID-ß PROTOFIBRILLER/OLIGOMERER |
JP5894939B2 (ja) | 2010-02-26 | 2016-03-30 | バイオアークティック ニューロサイエンス アーベー | プロトフィブリル結合抗体ならびにパーキンソン病、レビー小体型認知症および他のα−シヌクレイノパチーの治療および診断方法におけるこれらの使用 |
KR101849738B1 (ko) * | 2010-06-17 | 2018-04-17 | 트렐리스 바이오싸이언스 인코포레이티드 | 수동 인플루엔자 면역에 유용한 항체 |
EA034333B1 (ru) | 2010-11-30 | 2020-01-29 | Дженентек, Инк. | Варианты антитела для переноса соединения через гематоэнцефалический барьер |
WO2014033074A1 (en) * | 2012-08-29 | 2014-03-06 | F. Hoffmann-La Roche Ag | Blood brain barrier shuttle |
DK3041507T3 (da) * | 2013-08-26 | 2021-07-26 | Biontech Res And Development Inc | Nukleinsyrer, der koder for humane antistoffer mod sialyl-lewis a |
US10562973B2 (en) * | 2014-04-08 | 2020-02-18 | Prothena Bioscience Limited | Blood-brain barrier shuttles containing antibodies recognizing alpha-synuclein |
KR102564384B1 (ko) * | 2014-07-10 | 2023-08-07 | 바이오악틱 에이비 | 개선된 Aβ 프로토피브릴 결합 항체 |
-
2017
- 2017-07-13 WO PCT/EP2017/067727 patent/WO2018011353A1/en unknown
- 2017-07-13 SG SG11201810801QA patent/SG11201810801QA/en unknown
- 2017-07-13 JP JP2019501707A patent/JP2019529345A/ja active Pending
- 2017-07-13 KR KR1020197002785A patent/KR20190039696A/ko not_active Application Discontinuation
- 2017-07-13 AU AU2017297804A patent/AU2017297804A1/en not_active Abandoned
- 2017-07-13 SG SG10201912842VA patent/SG10201912842VA/en unknown
- 2017-07-13 MA MA045684A patent/MA45684A/fr unknown
- 2017-07-13 US US16/317,156 patent/US11498974B2/en active Active
- 2017-07-13 CN CN201780042832.1A patent/CN109476728A/zh active Pending
- 2017-07-13 BR BR112019000098-4A patent/BR112019000098A2/pt not_active Application Discontinuation
- 2017-07-13 CA CA3028035A patent/CA3028035A1/en not_active Abandoned
- 2017-07-13 MX MX2019000529A patent/MX2019000529A/es unknown
- 2017-07-13 EP EP17751619.2A patent/EP3484918A1/en active Pending
- 2017-07-13 RU RU2019102746A patent/RU2019102746A/ru not_active Application Discontinuation
-
2018
- 2018-11-21 PH PH12018502451A patent/PH12018502451A1/en unknown
- 2018-12-17 IL IL263773A patent/IL263773A/en unknown
-
2022
- 2022-06-30 JP JP2022106495A patent/JP2022130646A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
MX2019000529A (es) | 2020-01-15 |
US11498974B2 (en) | 2022-11-15 |
BR112019000098A2 (pt) | 2019-04-09 |
CA3028035A1 (en) | 2018-01-18 |
AU2017297804A1 (en) | 2019-01-24 |
RU2019102746A3 (ja) | 2020-11-30 |
KR20190039696A (ko) | 2019-04-15 |
US20190225699A1 (en) | 2019-07-25 |
IL263773A (en) | 2019-02-28 |
SG10201912842VA (en) | 2020-02-27 |
WO2018011353A1 (en) | 2018-01-18 |
JP2019529345A (ja) | 2019-10-17 |
EP3484918A1 (en) | 2019-05-22 |
CN109476728A (zh) | 2019-03-15 |
PH12018502451A1 (en) | 2019-09-30 |
RU2019102746A (ru) | 2020-08-14 |
MA45684A (fr) | 2019-05-22 |
SG11201810801QA (en) | 2019-01-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2022130646A (ja) | 脳送達タンパク質 | |
Hultqvist et al. | Bivalent brain shuttle increases antibody uptake by monovalent binding to the transferrin receptor | |
US11124563B2 (en) | Camelid single-domain antibody directed against phosphorylated tau proteins and methods for producing conjugates thereof | |
Fang et al. | High detection sensitivity with antibody-based PET radioligand for amyloid beta in brain | |
Syvänen et al. | A bispecific Tribody PET radioligand for visualization of amyloid-beta protofibrils–a new concept for neuroimaging | |
Syvänen et al. | Efficient clearance of Aβ protofibrils in AβPP-transgenic mice treated with a brain-penetrating bifunctional antibody | |
US9738712B2 (en) | Camelid single-domain antibody directed against amyloid beta and methods for producing conjugates thereof | |
Gustavsson et al. | SPECT imaging of distribution and retention of a brain-penetrating bispecific amyloid-β antibody in a mouse model of Alzheimer’s disease | |
US20150315267A1 (en) | A method of reducing brain amyloid plaques using anti-ab antibodies | |
JP6914655B2 (ja) | オリゴペプチド及びその接合体を製造する方法 | |
AU2017350947A1 (en) | Anti-ApoE antibodies | |
Bonvicini et al. | ImmunoPET imaging of amyloid-beta in a rat model of Alzheimer’s disease with a bispecific, brain-penetrating fusion protein |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220630 |
|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20220630 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20220816 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20230725 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20230919 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20240109 |
|
A02 | Decision of refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A02 Effective date: 20240312 |